AMD & Macular Health Research
Photobiomodulation Research Hub
Age-related macular degeneration (AMD) is the leading cause of vision loss in adults over 50, affecting millions worldwide. Our comprehensive research library documents over two decades of peer-reviewed evidence demonstrating how photobiomodulation—particularly at 670 nm and 810 nm wavelengths—can influence the mitochondrial, inflammatory, and structural pathways central to AMD progression.
This collection spans foundational mechanistic studies through modern clinical trials, tracking the evolution from laboratory discovery to therapeutic application. The research consistently demonstrates that targeted light therapy can enhance mitochondrial ATP production, reduce oxidative stress, modulate inflammatory cascades, and in clinical settings, improve visual function while reducing drusen burden.
The Spectral WaveFront's design is informed by this body of evidence, incorporating the wavelengths, fluence levels, and delivery protocols validated across these studies.
23
Total Studies
8
Clinical Trials
11
Animal Models
4
Review Articles
22
Years of Research
Research Timeline: From Discovery to Clinical Application
2003
Eells et al. – Methanol Toxicity Rescue
First demonstration that 670 nm light could rescue retinal function in toxicity models, establishing proof of concept for photobiomodulation in retinal disease.
2006
Feher et al. – Mitochondrial Alterations in AMD
Landmark study documenting mitochondrial dysfunction in RPE cells of AMD patients, establishing the mechanistic rationale for mitochondrial-targeted therapy.
2008
Ivandic & Ivandic – First AMD Clinical Results
Early clinical evidence showing visual acuity improvements in AMD patients treated with low-level laser therapy.
2012-2013
Mechanistic Breakthrough Studies
Series of studies (Kokkinopoulos, Begum, Rutar) elucidating how 670 nm light enhances mitochondrial membrane potential, upregulates cytochrome c oxidase, and reduces complement activation and inflammation.
2017
Merry et al. – Drusen Reduction Clinical Trial
Pivotal clinical trial demonstrating significant drusen volume reduction (−23%) alongside visual acuity and contrast sensitivity improvements using multi-wavelength PBM protocol.
2020
Grewal et al. – Aging & AMD Pilot
Demonstrated that 670 nm therapy improves rod function in healthy aging but shows differential effects in intermediate AMD, highlighting the importance of intervention timing.
2023
Jackson et al. – Systematic Review & Meta-Analysis
Comprehensive meta-analysis confirming safety and efficacy signals across multiple PBM trials for AMD, providing high-level evidence for therapeutic potential.
2024-2025
Modern Reviews & Integration
Contemporary reviews (Garg, Valter, Rosen) synthesizing two decades of evidence and discussing integration into clinical practice.
Key Clinical Trials: Comparative Outcomes
| Study | Dose / Protocol | Outcome |
|---|---|---|
| Merry 2017 | 670nm (4-7.7 J/cm²) + 590/790nm (0.1 J/cm²) 3-week treatment |
↓ Drusen volume (−23%); ↑ BCVA (+2 letters); ↑ contrast sensitivity |
| Merry 2012 | 670/590/790nm multi-wavelength Up to 12 months |
↑ Visual acuity (sustained); ↑ contrast sensitivity; benefits persist 1 year |
| Grewal 2020 | 670nm pilot study Single session |
↑ Rod function (healthy aging); mixed results in intermediate AMD |
| Ivandic 2008 | Low-level laser (red/NIR) Variable duration |
↑ VA in 95% dry AMD; ↑ in 60% wet AMD (203 eyes total) |
| Koev 2018 | Low-level laser 5-year follow-up |
Sustained improvements; long-term safety confirmed (63 patients) |
| Jackson 2023 | Systematic review & meta-analysis Multiple trials |
Safety and efficacy signals confirmed across AMD trials |
All study titles link to detail pages in our Research Library.
All AMD & Macular Health Research Articles
2024
Contemporary review surveying the landscape of PBM research for AMD and discussing clinical integration prospects.
2024
Comprehensive review of bench-to-bedside PBM research across ocular conditions, with significant AMD focus.
2023
Systematic review and meta-analysis comparing PBM therapy with sham treatment in AMD patients.
2023
Narrative review examining the pathophysiological mechanisms and clinical evidence for PBM in AMD.
2020
670 nm light therapy improves rod function in normal aging but may be less effective in intermediate AMD.
2018
Long-term safety and efficacy follow-up demonstrating sustained benefits and safety profile.
2017
Clinical trial demonstrating 23% drusen volume reduction with visual acuity and contrast sensitivity improvements.
2017
Demonstrates 25% improvement in aging retinal ERG responses with 670 nm treatment, linked to mitochondrial rescue.
2015
Shows near-infrared light corrects mitochondrial dysfunction in complement factor H knockout mice, an AMD-relevant genetic model.
2015
Demonstrates that 670 nm light enhances phagocytic capacity of human RPE cells, supporting clearance of photoreceptor outer segments.
2014
Demonstrates that 670 nm treatment directly increases ATP levels in aging eyes by optimizing mitochondrial respiration.
2013
Demonstrates that 670 nm light upregulates cytochrome c oxidase and reduces inflammatory markers in CFH−/− AMD model.
2013
Shows 670 nm light increases mitochondrial membrane potential and reduces age-related retinal inflammation via improved ATP production.
2013
Proposes PBM as addressing multiple AMD pathways simultaneously, moving beyond single-target approaches.
2012
PBM using 670 nm combined with lower-fluence 590/790 nm exposure demonstrated clinically meaningful improvements with benefits persisting up to one year.
2012
Examines long-term effects of low-level laser therapy showing sustained functional improvements in AMD patients.
In Your Cart
Your cart is empty